{"protocolSection": {"identificationModule": {"nctId": "NCT04195958", "orgStudyIdInfo": {"id": "ML41615"}, "organization": {"fullName": "Genentech, Inc.", "class": "INDUSTRY"}, "briefTitle": "A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma", "officialTitle": "A Multicenter, Open-Label, Single-Arm Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma", "acronym": "EDURO"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "TERMINATED", "whyStopped": "Due to low enrollment, this study was terminated early.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-11-30", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-10-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-10-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2019-12-09", "studyFirstSubmitQcDate": "2019-12-10", "studyFirstPostDateStruct": {"date": "2019-12-12", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-01-07", "resultsFirstSubmitQcDate": "2022-02-16", "resultsFirstPostDateStruct": {"date": "2022-03-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-02-16", "lastUpdatePostDateStruct": {"date": "2022-03-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Genentech, Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma. Exercise capacity will be assessed using cardiopulmonary exercise testing (CPET). Physical activity and sleep quality will be assessed with a wearable physical activity and sleep monitor. The study will consist of a 4-week screening period, a 24-week treatment period, and a 4-week safety follow-up. Approximately 60 participants will be enrolled, and omalizumab will be dosed according to the approved United States Package Insert (USPI) dosing table."}, "conditionsModule": {"conditions": ["Moderate-to-severe Allergic Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 3, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Omalizumab", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Omalizumab"]}], "interventions": [{"type": "DRUG", "name": "Omalizumab", "description": "Omalizumab will be administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency will be determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.", "armGroupLabels": ["Omalizumab"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline at Week 24 in Endurance Time (Minutes) During Cardiopulmonary Exercise Testing (CPET) at a Constant Work Rate (CWR)", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "timeFrame": "From Baseline to Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline at Week 24 in Physical Activity (Minutes/Day) as Assessed by a Wearable Physical Activity and Sleep Monitor", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Change From Baseline at Week 24 in Dynamic Hyperinflation at Isotime, as Measured by Inspiratory Capacity During CPET at a CWR", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Change From Baseline at Week 24 in Sleep Efficiency as Assessed by a Wearable Physical Activity and Sleep Monitor", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "timeFrame": "From Baseline to Week 24"}, {"measure": "Percentage of Participants With Adverse Events", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "timeFrame": "From Baseline to Week 28"}, {"measure": "Percentage of Participants With Serious Adverse Events", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "timeFrame": "From Baseline to Week 28"}, {"measure": "Percentage of Participants With Adverse Events Leading to Discontinuation of Omalizumab", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "timeFrame": "From Baseline to Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Physician-diagnosed asthma for at least 12 months prior to screening\n* Documented history of positive skin test or in vitro reactivity to a perennial aeroallergen\n* Able to comply with asthma control medication adherence, digital monitoring data collection, and eDiary requirements during screening period\n* Able to safely complete incremental exercise tolerance at screening\n* Pre-bronchodilator FEV1 of 40%-80% of predicted at screening\n* Documented history of variable airflow obstruction or hyper-responsiveness within 12 months of study entry\n* On inhaled corticosteroids (ICS) therapy at a total daily dose greater than or equal to (\u2265)500 micrograms (ug) of fluticasone propionate or equivalent and at least one second controller (LABA, LAMA, LTRA) for \u22653 months prior to screening\n* Uncontrolled asthma during the screening period, defined as an ACQ-5 \u22650.75 score\n* Sleep disturbance due to asthma (e.g. cough, wheezing etc.) in the opinion of the investigator\n* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or to use adequate contraception during the treatment period and for 60 days after the final dose of study drug.\n\nExclusion Criteria:\n\n* Known history of anaphylaxis/hypersensitivity to omalizumab\n* Treatment with investigational drugs within 12 weeks or 5 half-lives (whichever is longer) prior to screening\n* Treatment with monoclonal antibodies (e.g., omalizumab, mepolizumab, dupilumab) for 6 months prior to screening\n* Maintenance oral corticosteroid therapy, defined as daily or alternate-day oral corticosteroid within 3 months prior to screening or during the screening period\n* Treatment with systemic (oral, IV, or IM) corticosteroids within 4 weeks prior to screening or during the screening period\n* Isolated diagnosis of exercise induced asthma without chronic symptoms\n* History of interstitial lung disease, COPD, or other clinically significant lung disease other than asthma\n* Current malignancy or history of malignancy within 5 years prior to screening\n* Unable to complete cardiopulmonary exercise testing and/or perform physical activity due to underlying cardiac, neurologic or orthopedic conditions\n* Ongoing physician-treated sleep disorder that is unrelated to asthma within 6 months prior to screening\n* Current smoker or past smoker with \\>10 pack years\n* Known HIV infection at screening\n* Known acute or chronic infections with hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening\n* Infection that resulted in hospital admission, required treatment with intravenous or intramuscular antibiotics within 4 weeks prior to screening, or any active infection that required treatment with oral antibiotics within 2 weeks prior to screening\n* Active tuberculosis requiring treatment within 12 months prior to screening\n* History of alcohol, drug, or chemical abuse within 6 months of screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Clinical Trials", "affiliation": "Genentech, Inc.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Peninsula Research Associates", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "National Jewish Health", "city": "Denver", "state": "Colorado", "zip": "80206", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Broward Research Center", "city": "Pembroke Pines", "state": "Florida", "zip": "33024", "country": "United States", "geoPoint": {"lat": 26.00315, "lon": -80.22394}}, {"facility": "University of Iowa Hospitals & Clinics; Internal Medicine", "city": "Iowa City", "state": "Iowa", "zip": "52242", "country": "United States", "geoPoint": {"lat": 41.66113, "lon": -91.53017}}, {"facility": "University of Michigan", "city": "Ann Arbor", "state": "Michigan", "zip": "48109-0934", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Mayo Clinic - Rochester", "city": "Rochester", "state": "Minnesota", "zip": "55905", "country": "United States", "geoPoint": {"lat": 44.02163, "lon": -92.4699}}, {"facility": "Lenox Hill Hospital", "city": "New York", "state": "New York", "zip": "10075", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "American Health Research Inc.", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "University Hospitals Cleveland Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44016", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Temple Uni Medical Center; Pulmonary & Critical Care Medicine", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19140", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Spartanburg Medical Research", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Swedish Health Services", "city": "Seattle", "state": "Washington", "zip": "98122", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "Qualified researchers may request access to individual patient level data through the request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).\n\nFor further details on Roche's Global Policy on Sharing of Clinical Study Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study.", "groups": [{"id": "FG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "groups": [{"id": "BG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "0"}]}], "measures": [{"title": "Age, Continuous", "unitOfMeasure": "Years"}, {"title": "Sex: Female, Male", "classes": [{"categories": [{"title": "Female"}, {"title": "Male"}]}]}, {"title": "Race/Ethnicity, Customized"}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline at Week 24 in Endurance Time (Minutes) During Cardiopulmonary Exercise Testing (CPET) at a Constant Work Rate (CWR)", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "reportingStatus": "POSTED", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 24 in Physical Activity (Minutes/Day) as Assessed by a Wearable Physical Activity and Sleep Monitor", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "reportingStatus": "POSTED", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 24 in Dynamic Hyperinflation at Isotime, as Measured by Inspiratory Capacity During CPET at a CWR", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "reportingStatus": "POSTED", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Change From Baseline at Week 24 in Sleep Efficiency as Assessed by a Wearable Physical Activity and Sleep Monitor", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "reportingStatus": "POSTED", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Adverse Events", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "reportingStatus": "POSTED", "timeFrame": "From Baseline to Week 28", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Serious Adverse Events", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "reportingStatus": "POSTED", "timeFrame": "From Baseline to Week 28", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants With Adverse Events Leading to Discontinuation of Omalizumab", "description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "populationDescription": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on the low enrolment number and in order to protect and maintain participant privacy/confidentiality, no data is reported.", "reportingStatus": "POSTED", "timeFrame": "From Baseline to Week 24", "groups": [{"id": "OG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "From Baseline to Week 28", "description": "AEs were collected at each participant contact. Severity of AEs was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.", "eventGroups": [{"id": "EG000", "title": "Omalizumab", "description": "Omalizumab was administered by subcutaneous (SC) injection at a dose of 150 milligrams (mg) to 375 mg every 2 or 4 weeks. The dose and frequency was determined by body weight (kg) and the level of total IgE (IU/mL) measured during screening.", "deathsNumAffected": 0, "deathsNumAtRisk": 3, "seriousNumAffected": 0, "seriousNumAtRisk": 3, "otherNumAffected": 2, "otherNumAtRisk": 3}], "otherEvents": [{"term": "General Disorders", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 3}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "This study was terminated by the Sponsor. Only 3 participants were enrolled in this study. Based on this, there were not enough participants enrolled to perform a meaningful analysis."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the study but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."}, "pointOfContact": {"title": "Medical Communications", "organization": "Hoffmann-La Roche", "email": "genentech@druginfo.com", "phone": "800 821-8590"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2020-12-11", "uploadDate": "2022-01-07T14:59", "filename": "Prot_SAP_000.pdf", "size": 2704400}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-02-07", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000069444", "term": "Omalizumab"}], "ancestors": [{"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}], "browseLeaves": [{"id": "M413", "name": "Omalizumab", "asFound": "Enriched", "relevance": "HIGH"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}